Drugs / HLA-A2 restricted glioma antigen peptides vaccine
HLA-A2 restricted glioma antigen peptides vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01130077 | Feb 2009 → Nov 2024 | childhood brain stem glioma, childhood low-grade glioma, pediatric high-grade glioma | James Felker | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLA-A2 restricted glioma antigen peptides vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01130077 ↗ |
| Modality | Vaccine | “subcutaneous vaccinations with GAA epitope peptides” PMID 24888813 ↗ Jun 2014 |
| Route | Subcutaneous | “subcutaneous vaccinations with GAA epitope peptides” PMID 24888813 ↗ Jun 2014 |